{"id":926050,"date":"2026-01-11T15:03:14","date_gmt":"2026-01-11T20:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/"},"modified":"2026-01-11T15:03:14","modified_gmt":"2026-01-11T20:03:14","slug":"exagen-inc-announces-select-preliminary-2025-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/","title":{"rendered":"Exagen Inc. Announces Select Preliminary 2025 Financial Results"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CARLSBAD, Calif., Jan.  11, 2026  (GLOBE NEWSWIRE) &#8212; Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.<\/p>\n<p>\n        <strong>Select Preliminary Unaudited 2025 Results<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"5\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Revenue <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:39%;width:39%;min-width:39%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:30%;width:30%;min-width:30%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Three Months Ended<\/strong><br \/>\n            <br \/>\n            <strong>December 31, 2025<\/strong>\n          <\/td>\n<td colspan=\"2\" style=\"max-width:1%;width:1%;min-width:1%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"2\" style=\"max-width:30%;width:30%;min-width:30%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Twelve Months Ended<\/strong><br \/>\n            <br \/>\n            <strong>December 31, 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Total Revenue<\/strong>\n          <\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>$16M to $17M<\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>$66M to $67M<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <em>Year-Over-Year Growth<\/em>\n          <\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>17% to 24%<\/em>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <em>19% to 20%<\/em>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"4\" style=\"max-width:70%;width:70%;min-width:70%;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"max-width:30%;width:30%;min-width:30%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Other <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"4\" style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>Twelve Months Ended<\/strong><br \/>\n            <strong><br \/>\n              <br \/>December 31, 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: top\">AVISE CTD Volume<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">136,000 to 137,000<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: top\">AVISE CTD Trailing 12-month (TTM) average selling price<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">$441 to $445<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\" style=\"vertical-align: top\">Year-end cash and cash equivalents<\/td>\n<td colspan=\"2\" style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">$32M<\/td>\n<\/tr>\n<tr>\n<td colspan=\"5\">\u00a0<\/td>\n<td colspan=\"2\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>The select preliminary unaudited financial results reported today represent:<\/p>\n<ul type=\"disc\">\n<li>Record full year 2025 revenue, an increase of at least 19% over 2024<\/li>\n<li>AVISE CTD trailing 12-month (TTM) ASP expansion by at least $30 compared to 2024<\/li>\n<li>AVISE CTD test volume growth of at least 13,000, an 11% increase over 2024<\/li>\n<li>Year-end cash and cash equivalents of $32 million, a $10 million increase over 2024<\/li>\n<\/ul>\n<p align=\"justify\">\u201cI am pleased to report the completion of another strong year for Exagen in which we\u2019ve continued to make substantial progress in building a great company; a testament to continued execution across our commercial, scientific, and operational teams,\u201d said John Aballi, President and CEO. \u201cBased upon our preliminary results, we delivered significant topline growth, driven by both volume and ASP expansion, despite unexpected ASP headwinds in the second half of the year. We also strengthened our scientific and commercial teams and subsequently launched our first enhancements to the AVISE platform in several years, with more on the horizon. Our strong cash position and disciplined approach provide the flexibility to continue to invest in innovation and advance our strategy to change the standard of care in autoimmune disease while pursuing our goal of operating a profitable company.\u201d<\/p>\n<p>\n        <strong>Cautionary Note Regarding Select Preliminary Unaudited Financial Results<\/strong>\n      <\/p>\n<p>Exagen is providing the above select preliminary unaudited financial information and results of operations as of and for the three months and year ended December 31, 2025, based on currently available information. The company\u2019s financial closing procedures with respect to the estimated financial data provided above are not yet complete. These procedures often result in changes to accounts. The company\u2019s independent registered public accounting firm has not audited, reviewed, compiled or performed any procedures with respect to the select preliminary unaudited financial information and, accordingly, our independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto. As a result, the company\u2019s final results may vary from the preliminary results presented above. Management undertakes no obligation to update or supplement the information provided above until it releases its audited financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP) for the year ended December 31, 2025.<\/p>\n<p>\n        <strong>About Exagen<\/strong>\n      <\/p>\n<p>Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen\u2019s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company\u2019s flagship product, AVISE\u00ae CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sj\u00f6gren\u2019s syndrome earlier and with greater accuracy. Exagen\u2019s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.<\/p>\n<p>For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p>Exagen cautions you that statements contained in this press release\u00a0regarding\u00a0matters that are not historical facts are forward-looking statements. These statements are based on\u00a0Exagen\u2019s\u00a0current beliefs\u00a0and expectations. Such forward-looking statements include, but are not limited to, statements regarding:\u00a0Exagen\u2019s\u00a0goals, strategies and ambitions; the potential utility and effectiveness of\u00a0Exagen\u2019s\u00a0services and testing solutions, additional enhancements to the AVISE platform; potential shareholder value and growth and profitability; preliminary financial information for 2025. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in\u00a0Exagen\u2019s\u00a0business, including, without limitation:\u00a0delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests;\u00a0Exagen\u2019s\u00a0commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community;\u00a0Exagen\u2019s\u00a0ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for\u00a0Exagen\u2019s\u00a0testing products, including\u00a0Exagen\u2019s\u00a0ability to collect on funds due;\u00a0Exagen\u2019s\u00a0ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting\u00a0Exagen\u2019s\u00a0business; and other risks described in\u00a0Exagen\u2019s\u00a0prior press releases and\u00a0Exagen\u2019s\u00a0filings with the Securities and Exchange Commission (SEC), including under the heading \u201cRisk Factors\u201d in\u00a0Exagen\u2019s\u00a0Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 11, 2025, Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the SEC on November 4, 2025 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof.\u00a0All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Jeff Black, Chief Financial Officer<br \/>Exagen Inc.<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aTIO_zftq4tN4RRTuk5Lymc2jVVO411SJLYl_0gBL7tODQy0QDjCmSkvgdszm2J5VoDNwJI8idz9FOshERvaQw==\" rel=\"nofollow\" target=\"_blank\">ir@exagen.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODMwN2Q5NDUtNjQ3Ny00NmI2LThiNmMtOWQ0ZjY1ODg3NmQ4LTEwMjI1NDUtMjAyNi0wMS0xMS1lbg==\/tiny\/Exagen-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) &#8212; Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance. Select Preliminary Unaudited 2025 Results \u00a0 Revenue \u00a0 Three Months Ended December 31, 2025 \u00a0 Twelve Months Ended December 31, 2025 Total Revenue $16M to $17M \u00a0 $66M to $67M Year-Over-Year Growth 17% to 24% \u00a0 19% to 20% \u00a0 Other \u00a0 Twelve Months Ended December 31, 2025 AVISE CTD Volume 136,000 to 137,000 AVISE CTD Trailing 12-month (TTM) average selling price $441 to $445 Year-end cash and cash equivalents $32M \u00a0 \u00a0 The select preliminary unaudited financial results &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Exagen Inc. Announces Select Preliminary 2025 Financial Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-926050","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exagen Inc. Announces Select Preliminary 2025 Financial Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exagen Inc. Announces Select Preliminary 2025 Financial Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) &#8212; Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance. Select Preliminary Unaudited 2025 Results \u00a0 Revenue \u00a0 Three Months Ended December 31, 2025 \u00a0 Twelve Months Ended December 31, 2025 Total Revenue $16M to $17M \u00a0 $66M to $67M Year-Over-Year Growth 17% to 24% \u00a0 19% to 20% \u00a0 Other \u00a0 Twelve Months Ended December 31, 2025 AVISE CTD Volume 136,000 to 137,000 AVISE CTD Trailing 12-month (TTM) average selling price $441 to $445 Year-end cash and cash equivalents $32M \u00a0 \u00a0 The select preliminary unaudited financial results &hellip; Continue reading &quot;Exagen Inc. Announces Select Preliminary 2025 Financial Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-11T20:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Exagen Inc. Announces Select Preliminary 2025 Financial Results\",\"datePublished\":\"2026-01-11T20:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/\"},\"wordCount\":981,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/\",\"name\":\"Exagen Inc. Announces Select Preliminary 2025 Financial Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=\",\"datePublished\":\"2026-01-11T20:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/exagen-inc-announces-select-preliminary-2025-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exagen Inc. Announces Select Preliminary 2025 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exagen Inc. Announces Select Preliminary 2025 Financial Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Exagen Inc. Announces Select Preliminary 2025 Financial Results - Market Newsdesk","og_description":"CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) &#8212; Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance. Select Preliminary Unaudited 2025 Results \u00a0 Revenue \u00a0 Three Months Ended December 31, 2025 \u00a0 Twelve Months Ended December 31, 2025 Total Revenue $16M to $17M \u00a0 $66M to $67M Year-Over-Year Growth 17% to 24% \u00a0 19% to 20% \u00a0 Other \u00a0 Twelve Months Ended December 31, 2025 AVISE CTD Volume 136,000 to 137,000 AVISE CTD Trailing 12-month (TTM) average selling price $441 to $445 Year-end cash and cash equivalents $32M \u00a0 \u00a0 The select preliminary unaudited financial results &hellip; Continue reading \"Exagen Inc. Announces Select Preliminary 2025 Financial Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-11T20:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Exagen Inc. Announces Select Preliminary 2025 Financial Results","datePublished":"2026-01-11T20:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/"},"wordCount":981,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/","name":"Exagen Inc. Announces Select Preliminary 2025 Financial Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=","datePublished":"2026-01-11T20:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMzMzOSM3MzU0NTA4IzIwMTA5NzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/exagen-inc-announces-select-preliminary-2025-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Exagen Inc. Announces Select Preliminary 2025 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=926050"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/926050\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=926050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=926050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=926050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}